36-bed student apartment development proposed on Ann Arbor’s Main Street

ANN ARBOR, MI — Two houses on Ann Arbor’s Main Street are proposed to be demolished to make way for a 36-bed apartment building catering to University of Michigan students.

The city’s Planning Commission voted 6-0 Tuesday night, Dec. 1, to recommend City Council approve the development.

The project is proposed on the east side of Main Street, just south of Davis Avenue and south of downtown.

Two-story rental houses at 907 and 913 S. Main St. would be torn down and replaced by a three-story, 13,467-square-foot building containing six six-bedroom apartments.

The project is allowed under the existing multi-family zoning, maxing out a 30-foot height limit.

Each of the tri-level units would include six bathrooms, two kitchens and two living areas.

Commission Chair Sarah Mills complimented the development team on what she considered a super creative and smart design, making special note of the dual kitchens.

Commissioner Alex Milshteyn

Read More

Egg Harbor convenience store sold for new condo and retail development

CLOSE

EGG HARBOR – The way is clear for a new condominium/retail mixed-use development downtown, after the sale of a longstanding business and its 97-year-old stone building was recently finalized.

Mueller’s Mini Mart convenience store is now closed, and its building will be retained and upgraded following its sale to The Residences of Egg Harbor, LLC, a consortium of four brokers and developers with Creative Business Services/CBS-Global in Green Bay.

Developers Tom Martin, Michael Schwantes and Bob Wolter of Green Bay-based Creative Business Services/CBS-Global completed their purchase of Mueller’s Mini Mart convenience store in Egg Harbor, with plans to redevelop the property into condominiums and retail space under the name The Residences of Egg Harbor. Shown from left in front of the store are Bob Mueller, Jr., Schwantes, Mary Mueller, Wolter and Martin. (Photo: Courtesy Creative Building Services)

The original proposal for The Residences, announced in January, called for a

Read More

Valneva Announces Acceleration of Pediatric Development for Lyme Disease Vaccine Candidate

 

  • Phase 2 study VLA15-221 planned to be initiated in Q1 2021, subject to regulatory approval
    • First clinical study of VLA15 that includes a pediatric population, aged 5-17 years
    • Study will include participants from 5-65 years of age and a reduced immunization schedule (Month 0-6 compared to Month 0-2-6)
    • The study will trigger a milestone payment, upon dosing of the first subject, from Pfizer to Valneva of $10 million
  • Phase 3 pivotal efficacy trial is planned to commence in 2022

Saint-Herblain (France), December 2, 2020 – Valneva SE (“Valneva”), a specialty vaccine company focused on prevention of diseases with major unmet needs, today announced its plans to accelerate pediatric development of its Lyme vaccine candidate, VLA15, in collaboration with Pfizer Inc. (NYSE: PFE), with the planned initiation of study VLA15-221 in the first quarter of 2021, subject to regulatory approval.

VLA15-221 is planned as a randomized, observer-blind, placebo-controlled Phase 2 study.

Read More

SutimCo Inc: New Software Development and Business acquisition Secured Encryption Software Acquisition and Developments

DALLAS, Dec. 2, 2020 /PRNewswire/ — SutimCo Inc. (OTC PK: SUTI) (“The Company”) The company is pleased to announce updates to the new business plan and a master development program for 2020 and 2021.

Online identity theft is a multi-billion-dollar problem. According to some sources it’s around $16,000,000,000 and over 650,000 cases in 2019/2020. When researching the problem, it becomes very apparent why it’s such a massive problem and why it hasn’t got better.

Sutimco International Inc. has acquired technology that could change the game forever. This technology is groundbreaking and patent pending. The acquired technology addresses 3 specific areas of why identity is stolen: how data is collected, stored, and retrieved.

When your data is gathered by Sutimco, it will be encrypted with an image-based, dynamically driven 2048+ bit next-generation blockchain encryption prior to it ever being submitted through a network or system, once the data arrives at

Read More

BMW R18-based ‘Transcontinental’ under development: What to expect from this full-size bagger!

BMW Motorrad seems to be working on a full-sized bagger and in most certainty, it will be called the Transcontinental. Here’s what all to expect and how it will look like.

BMW Transcontinental (Image source: bennetts.co.uk)

 

BMW is working on a new full-sized bagger motorcycle and the same might be called Transcontinental. Even before BMW officially revealed the R18, leaked design drawings on the web suggested that the company is working on two bikes on the same platform out of which one is a cruiser while the other one, a bagger. That said, the Transcontinental will be the other bike that we mentioned. The company has recently applied for European trademark rights for ‘Transcontinental’ name. Some patent images, courtesy Bennetts, have now leaked on the web revealing many details. The tubular steel frame on the bike looks updated while the bodywork is completely different than the R18. Upfront, one can

Read More

Regulus Therapeutics Collaborates With Bio-Techne For Biomarker Development

MINNEAPOLIS, Dec. 2, 2020 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics (NASDAQ: RGLS) announced a collaboration to support Regulus with biomarker analysis for the clinical development of RGLS4326, an Autosomal Dominant Polycystic Kidney Disease (ADPKD) treatment.

Regulus has utilized two Bio-Techne branded product lines, ProteinSimple and Exosome Diagnostics, to aid in their clinical trial patient testing.  RGLS4326 is a first in class anti-miR-17 therapy currently in Phase 1b clinical development in ADPKD patients. The Phase 1b trial is an adaptive design, open-label, multiple dose study in up to three cohorts of patients with ADPKD. This study will evaluate RGLS4326 for safety, pharmacokinetics, and pharmacodynamic effects on the levels of polycystin 1 (PC1) and polycystin 2 (PC2). Due to a mutation in the PKD genes, patients with ADPKD have been reported to have low levels of PC1 and PC2, the proteins encoded by the PKD1 and PKD2 genes,

Read More

Pininfarina gives glimpse at 1,877-horsepower Battista’s development, including Nardo testing

Italian design house and coachbuilder Pininfarina in 2018 launched its own car brand specializing in high-performance, ultra-luxury vehicles with electric powertrains.

The first model is the Battista, a hypercar to rival the Bugatti Chiron and which 150 customers around the world will get to call their own.

Pininfarina rolled out a prototype of the Battista at the 2019 Geneva International Motor Show and since then the car has undergone rigorous testing, including extensive sessions in the wind tunnel and at racetracks around Europe. The most recent track session was at Italy’s Nardo high-speed oval, and behind the wheel was Georgios Syropoulos, Pininfarina’s official test driver and head of vehicle dynamics.

“The phenomenal performance potential of the Battista is clear,” Syropoulos said in a statement. “Our clients will never have experienced acceleration like this before.”

Pininfarina Battista prototype

Pininfarina Battista prototype

Pininfarina’s specs for the Battista include a 0-60 mph of less than 2.0

Read More

Actinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical Development

The MarketWatch News Department was not involved in the creation of this content.


NEW YORK, Dec. 1, 2020 /PRNewswire via COMTEX/ —
NEW YORK, Dec. 1, 2020 /PRNewswire/ — Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”) today announced the appointment of Mary Mei Chen, M.D., Ph.D. to the position of Vice President of Clinical Development, effective immediately. In this role, Dr. Chen will lead the clinical development of Actinium’s CD33 program including the Actimab-A plus CLAG-M and Actimab-A plus venetoclax combination trials in relapsed and refractory Acute Myeloid Leukemia (“R/R AML”). Dr. Chen joins Actinium from GlycoMimetics, where she played a leading role in multiple clinical trials including the global pivotal Phase 3 study of uproleselan (GMI-1271-301). In addition to working on Actimab-A development, Dr. Chen will also utilize her training in immunology and experience in translational medicine to identify areas of synergy between targeted radiotherapy with

Read More

Henrico County endorses billion-dollar ‘eco-district’ development with 17,000 seat arena

HENRICO COUNTY, Va. (WWBT) – Henrico County officials are endorsing a developer’s vision for GreenCity, a $2.3 billion private, mixed-use “eco-district” development that would promote economic development and environmental sustainability as well as include a 17,000-seat arena for major concerts, sporting events and other entertainment.

The development would integrate extensive parks, trails and open spaces among about 2 million square feet of office space, 280,000 square feet of retail space, 2,400 housing units, two hotels and a $250 million arena.

Officials with Henrico and GreenCity LLC announced plans for development Tuesday at the county-owned former headquarters of Best Products, which is northeast of East Parham Road’s interchange with Interstate 95 and where the 250-acre community would extend north to Interstate 295.

“GreenCity will be a community that preserves, embraces and showcases open space, and it will drive economic development and tourism in new and exciting ways while remaining respectful to

Read More

Boom Supersonic all-in on Amazon AWS for aircraft design, development

A rendering of Boom Supersonic’s Overture jet.

Boom Supersonic

Amazon Web Services announced on Tuesday that Boom Supersonic is going ‘all-in’ as a cloud-computing customer, which the aviation start-up says will power the design, development and manufacturing of its next-generation jet.

Boom founder and CEO Blake Scholl told CNBC that the deal with AWS represents his company deepening its relationship with Amazon, with Boom expanding its use of cloud-computing to “new high performance instances” that will “further upgrade our ability to run simulations rapidly and inexpensively.”

“We’ve been working with [AWS] behind the scenes for several years, with 53 million compute hours running virtual wind tunnel tests,” Scholl said.

Boom declined to the specify the length or value of the contract it signed with AWS. But the deal represents one of the first public moves by the Aerospace and Satellite Solutions unit that AWS established in June. The unit is

Read More